Company Summary

Symbiotix Biotherapies, Inc. is a pioneering microbiome company founded on the basis of over two decades of research at California Institute of Technology, Brigham & Women’s Hospital, Harvard Medical School and Dartmouth College. Symbiotix is developing a novel class of Treg-modulating therapeutics based on molecules derived from the human microbiome. As one of the earliest companies in the microbiome sector, the company’s most advanced clinical candidate has been described in over 100 scientific publications, represents the most well studied microbiome-derived molecule to date, and is now protected by issued composition-of-matter patents. Symbiotix is dedicated to delivering first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases.

Year Founded:  2009

Key Executives:
• Sarkis Mazmanian, Ph.D. (Caltech) – Co-Founder and Director
• Dennis Kasper, M.D. (Harvard Medical School) – Co-Founder and Director
• Lloyd Kasper, M.D. (Dartmouth) – Co-Founder
• Sheila Mikhail, J.D., MBA – Executive Chairman
• Nader Yaghoubi, M.D., Ph.D. – President and Chief Executive Officer

Location:  Boston, MA

Website:  http://symbiotix-bio.com/

Company Status:  Private

Year Invested:  2017

Investment Status:  Current

Board Member:  Peter Alff